CU20100216A7 - Polipéptidos derivados de la il-2 con actividad agonista y mayor eficacia para la terapia del cáncer e infecciones crónicas - Google Patents

Polipéptidos derivados de la il-2 con actividad agonista y mayor eficacia para la terapia del cáncer e infecciones crónicas

Info

Publication number
CU20100216A7
CU20100216A7 CU20100216A CU20100216A CU20100216A7 CU 20100216 A7 CU20100216 A7 CU 20100216A7 CU 20100216 A CU20100216 A CU 20100216A CU 20100216 A CU20100216 A CU 20100216A CU 20100216 A7 CU20100216 A7 CU 20100216A7
Authority
CU
Cuba
Prior art keywords
present
polypeptides
relates
disclosed
cancer
Prior art date
Application number
CU20100216A
Other languages
English (en)
Other versions
CU23923B1 (es
Inventor
Escalona Neris Michel Enamorado
Rodriguez Saumel Perez
Monzon Kalet Leon
Portilla Tania Carmenate
Davila Agustin Bienvenido Lage
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45350376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20100216(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Priority to CU2010000216A priority Critical patent/CU23923B1/es
Priority to MYPI2013700752A priority patent/MY171356A/en
Priority to UAA201307450A priority patent/UA106318C2/ru
Priority to MX2013005250A priority patent/MX346222B/es
Priority to KR1020137012452A priority patent/KR101559330B1/ko
Priority to US13/885,021 priority patent/US9206243B2/en
Priority to CN201180054156.2A priority patent/CN103201284B/zh
Priority to PE2013001054A priority patent/PE20140382A1/es
Priority to PCT/CU2011/000007 priority patent/WO2012062228A2/es
Priority to EP11797102.8A priority patent/EP2639241B1/en
Priority to EA201390681A priority patent/EA026022B1/ru
Priority to CA2814814A priority patent/CA2814814C/en
Priority to ES11797102.8T priority patent/ES2543915T3/es
Priority to JP2013538062A priority patent/JP5761831B2/ja
Priority to AU2011328688A priority patent/AU2011328688B2/en
Priority to BR112013010127-0A priority patent/BR112013010127B1/pt
Priority to HK13109794.4A priority patent/HK1182403B/xx
Priority to PH1/2013/500937A priority patent/PH12013500937A1/en
Priority to TW100141299A priority patent/TWI488864B/zh
Priority to ARP110104234A priority patent/AR083858A1/es
Publication of CU20100216A7 publication Critical patent/CU20100216A7/es
Priority to CO13103448A priority patent/CO6700862A2/es
Priority to CL2013001107A priority patent/CL2013001107A1/es
Priority to IL226221A priority patent/IL226221B/en
Publication of CU23923B1 publication Critical patent/CU23923B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a polipéptidos que comparten secuencia primaria con la IL-2 humana, excepto porque varios aminoácidos han sido mutados. Las mutaciones introducidas reducen sustancialmente la capacidad de estos polipéptidos para estimular in vitro e in vivo a las células T reguladoras (T CD4+CD5+FoxP3+) y le confieren una mayor eficacia en la terapia de tumores trasplantables murinos. La presente invención incluye además las aplicaciones terapéuticas de estas variantes mutadas, solas o en combinación con vacunas, para la terapia de enfermedades como el cáncer o infecciones donde la actividad de las células T reguladoras (Tregs) es relevante. La presente invención también se relaciona con plopéptidos específicos cuya secuencia de aminoácidos es divulgada en la presente invención. En otro aspecto la presente invención se relaciona con las composiciones farmacéuticas que comprenden como principio activo los polipéptidos divulgados. Por último, la presente invención se relaciona con el uso terapéutico de los polipéptidos y composiciones farmacéuticas divulgados dado su efecto modulador del sistema inmune sobre patologías como cáncer y enfermedades infecciosas crónicas.
CU2010000216A 2010-11-12 2010-11-12 Polipéptidos derivados de la il-2 con actividad agonista CU23923B1 (es)

Priority Applications (23)

Application Number Priority Date Filing Date Title
CU2010000216A CU23923B1 (es) 2010-11-12 2010-11-12 Polipéptidos derivados de la il-2 con actividad agonista
HK13109794.4A HK1182403B (en) 2010-11-12 2011-11-10 Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections
EA201390681A EA026022B1 (ru) 2010-11-12 2011-11-10 Производные полипептиды il-2 с агонистической активностью для лечения рака
ES11797102.8T ES2543915T3 (es) 2010-11-12 2011-11-10 Polipéptidos derivados de la IL-2 con actividad agonista para la terapia del cáncer e infecciones crónicas
MX2013005250A MX346222B (es) 2010-11-12 2011-11-10 Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas.
KR1020137012452A KR101559330B1 (ko) 2010-11-12 2011-11-10 암 및 만성 감염 치료를 위한, 효능제 활성을 갖는 인터루킨 2로부터 유도된 폴리펩티드
US13/885,021 US9206243B2 (en) 2010-11-12 2011-11-10 IL-2 derivative polypeptides
CN201180054156.2A CN103201284B (zh) 2010-11-12 2011-11-10 用于癌症和慢性感染的治疗的具有激动剂活性的衍生自il-2的多肽
PE2013001054A PE20140382A1 (es) 2010-11-12 2011-11-10 Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas
PCT/CU2011/000007 WO2012062228A2 (es) 2010-11-12 2011-11-10 Polipéptidos derivados de la il-2 con actividad agonista para la terapia del cáncer e infecciones crónicas.
EP11797102.8A EP2639241B1 (en) 2010-11-12 2011-11-10 Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections
MYPI2013700752A MY171356A (en) 2010-11-12 2011-11-10 Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections
CA2814814A CA2814814C (en) 2010-11-12 2011-11-10 Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections
UAA201307450A UA106318C2 (ru) 2010-11-12 2011-11-10 Производный полипептид il-2 с агонистической активностью для лечения рака и хронических инфекций
JP2013538062A JP5761831B2 (ja) 2010-11-12 2011-11-10 癌及び慢性感染の治療のための作動薬活性を有するｉｌ−２由来のポリペプチド
AU2011328688A AU2011328688B2 (en) 2010-11-12 2011-11-10 Polypeptides derived from IL-2 having agonist activity, for the therapy of cancer and chronic infections
BR112013010127-0A BR112013010127B1 (pt) 2010-11-12 2011-11-10 Polipeptídeo agonista da interleucina 2, proteína de fusão, composição farmacêutica útil na terapia do câncer e enfermidades infecciosas crônicas, e, uso do polipeptídeo
ARP110104234A AR083858A1 (es) 2010-11-12 2011-11-11 Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas
PH1/2013/500937A PH12013500937A1 (en) 2010-11-12 2011-11-11 Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections
TW100141299A TWI488864B (zh) 2010-11-12 2011-11-11 用於治療癌症及慢性感染之具有促效劑活性之介白素－２（ｉｌ－２）衍生物多肽
CO13103448A CO6700862A2 (es) 2010-11-12 2013-04-23 Polipéptidos derivados de la il-2 con actividad agonista para la terapia del cáncer e infecciones crónicas.
CL2013001107A CL2013001107A1 (es) 2010-11-12 2013-04-23 Polipeptido derivado de la il-2 con actividad agonista; proteina de fusion que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar cancer y enfermedades infecciosas cronicas.
IL226221A IL226221B (en) 2010-11-12 2013-05-07 Polypeptides derived from 2-il have agonistic activity, for the cure of cancer and chronic inflammations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2010000216A CU23923B1 (es) 2010-11-12 2010-11-12 Polipéptidos derivados de la il-2 con actividad agonista

Publications (2)

Publication Number Publication Date
CU20100216A7 true CU20100216A7 (es) 2012-06-21
CU23923B1 CU23923B1 (es) 2013-07-31

Family

ID=45350376

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2010000216A CU23923B1 (es) 2010-11-12 2010-11-12 Polipéptidos derivados de la il-2 con actividad agonista

Country Status (22)

Country Link
US (1) US9206243B2 (es)
EP (1) EP2639241B1 (es)
JP (1) JP5761831B2 (es)
KR (1) KR101559330B1 (es)
CN (1) CN103201284B (es)
AR (1) AR083858A1 (es)
AU (1) AU2011328688B2 (es)
BR (1) BR112013010127B1 (es)
CA (1) CA2814814C (es)
CL (1) CL2013001107A1 (es)
CO (1) CO6700862A2 (es)
CU (1) CU23923B1 (es)
EA (1) EA026022B1 (es)
ES (1) ES2543915T3 (es)
IL (1) IL226221B (es)
MX (1) MX346222B (es)
MY (1) MY171356A (es)
PE (1) PE20140382A1 (es)
PH (1) PH12013500937A1 (es)
TW (1) TWI488864B (es)
UA (1) UA106318C2 (es)
WO (1) WO2012062228A2 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
HUE029139T2 (hu) 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
KR102042246B1 (ko) 2014-02-06 2019-11-28 에프. 호프만-라 로슈 아게 인터류킨-2 융합 단백질 및 이의 용도
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
SI3134127T1 (sl) * 2014-04-25 2020-06-30 Rinat Neuroscience Corp. Konjugati zdravil s protitelesi z visoko stopnjo zdravila
WO2016025385A1 (en) 2014-08-11 2016-02-18 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
US20190275133A1 (en) * 2016-11-10 2019-09-12 Nektar Therapeutics Immunotherapeutic tumor treatment method
CU24483B1 (es) 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
CA3055200A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
AU2018287317B2 (en) * 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
US20200299349A1 (en) 2017-11-21 2020-09-24 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US11319355B2 (en) * 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
WO2019173832A2 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
CU24554B1 (es) * 2018-05-07 2021-11-04 Ct Inmunologia Molecular Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
US11492384B2 (en) * 2018-09-17 2022-11-08 Gi Innovation, Inc. Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
CN120463822A (zh) 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
US12378295B2 (en) 2018-10-29 2025-08-05 1Globe Biomedical Co., Ltd. Rationally designed protein compositions
BR112021010983A2 (pt) 2018-12-21 2021-08-31 Jiangsu Hengrui Medicine Co., Ltd. Variante de interleucina-2 humana ou seu derivado
CU24712B1 (es) * 2019-03-15 2024-07-10 Centre Hospitalier Univ Vaudois Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
EP3980033A4 (en) 2019-06-05 2023-08-23 Emory University PHOTOLYSIS TO UNLOCK CAGED PROTEIN-LIKE THERAPEUTIC AGENTS
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
CA3143034A1 (en) * 2019-06-14 2020-12-17 Cugene Inc. Novel interleukin-2 variants for the treatment of cancer
US20220356221A1 (en) 2019-09-28 2022-11-10 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
WO2021142471A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
EP4090674A4 (en) 2020-01-14 2024-01-24 Synthekine, Inc. Biased il2 muteins methods and compositions
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
AR121891A1 (es) 2020-04-22 2022-07-20 Merck Sharp & Dohme CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 bgᶜ Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO
JPWO2022059794A1 (es) * 2020-09-18 2022-03-24
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4232071A4 (en) 2020-10-23 2024-08-28 Asher Biotherapeutics, Inc. FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
CN116234912A (zh) 2020-11-13 2023-06-06 江苏恒瑞医药股份有限公司 一种包含人白细胞介素2变体或其衍生物的药物组合物及其用途
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
US20230181754A1 (en) 2021-07-09 2023-06-15 Bright Peak Therapeutics Ag Modified checkpoint inhibitors and uses thereof
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
WO2023281479A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Checkpoint inhibitors conjugated to il-2, and uses thereof
WO2023005680A1 (zh) 2021-07-30 2023-02-02 西安龙腾景云生物科技有限公司 一种人白细胞介素2变体及其用途
CU24763B1 (es) * 2021-12-21 2025-07-09 Ct Inmunologia Molecular Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
US20250215452A1 (en) 2022-03-25 2025-07-03 Universität Zürich Adenoviral Mediated Targeting of Activated Immune Cells
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
CN115850436B (zh) * 2022-10-14 2026-02-03 海徕科(北京)生物技术有限公司 白介素2突变体及其应用
WO2024119193A2 (en) 2022-12-02 2024-06-06 AskGene Pharma, Inc. Mutant il-2 polypeptides and il-2 prodrugs
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
FR2624741B1 (fr) * 1987-12-21 1991-06-28 Pasteur Institut Compositions a base d'une combinaison de liposomes et de lymphokine presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire
DE68927679T2 (de) * 1988-10-27 1997-06-26 Univ Minnesota Immunhilfsmittel aus Liposome enthaltend Lymphokin IL -2
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
WO2005007121A2 (en) * 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
CN1609227A (zh) * 2003-10-24 2005-04-27 中国科学院沈阳应用生态研究所 一种白介素－4突变基因il－4－13及其制备和应用
EP1750746A1 (en) * 2004-06-04 2007-02-14 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
CA2656700A1 (en) * 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
WO2009061853A2 (en) * 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
MX2011007647A (es) * 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.

Also Published As

Publication number Publication date
AU2011328688A1 (en) 2013-05-02
MY171356A (en) 2019-10-10
CN103201284A (zh) 2013-07-10
AU2011328688B2 (en) 2015-05-14
KR20130091346A (ko) 2013-08-16
IL226221B (en) 2018-10-31
BR112013010127B1 (pt) 2021-12-14
PH12013500937A1 (en) 2017-08-23
CU23923B1 (es) 2013-07-31
US9206243B2 (en) 2015-12-08
AR083858A1 (es) 2013-03-27
WO2012062228A2 (es) 2012-05-18
CA2814814C (en) 2015-12-22
IL226221A0 (en) 2013-07-31
HK1182403A1 (en) 2013-11-29
CO6700862A2 (es) 2013-06-28
CL2013001107A1 (es) 2014-01-10
JP2014500868A (ja) 2014-01-16
KR101559330B1 (ko) 2015-10-12
EA201390681A1 (ru) 2013-08-30
MX346222B (es) 2017-03-09
CN103201284B (zh) 2015-07-01
JP5761831B2 (ja) 2015-08-12
ES2543915T3 (es) 2015-08-25
WO2012062228A3 (es) 2012-07-05
TW201300409A (zh) 2013-01-01
EA026022B1 (ru) 2017-02-28
US20140314709A1 (en) 2014-10-23
EP2639241B1 (en) 2015-07-08
PE20140382A1 (es) 2014-03-24
TWI488864B (zh) 2015-06-21
BR112013010127A2 (pt) 2016-08-30
EP2639241A2 (en) 2013-09-18
MX2013005250A (es) 2013-08-29
CA2814814A1 (en) 2012-05-18
UA106318C2 (ru) 2014-08-11

Similar Documents

Publication Publication Date Title
CU20100216A7 (es) Polipéptidos derivados de la il-2 con actividad agonista y mayor eficacia para la terapia del cáncer e infecciones crónicas
CU23734A1 (es) Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
EA201101518A1 (ru) Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии
ECSP14012676A (es) Compuestos de carbamato y preparación y uso de los mismos
IN2012DN06720A (es)
MD4577B1 (ro) Compoziţii masticabile de uz veterinar care conţin agent activ izoxazolinic şi utilizarea acestora în tratamentul sau prevenirea unei infestări sau infecţii parazitare
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
MY188139A (en) Sodium channel modulators for the treatment of pain
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
BR112014011981A8 (pt) Formulações farmacêuticas sólidas orais, seus processos de preparação e usos
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
TR200900878A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
EA201590697A1 (ru) Производные кетамина
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
UY35091A (es) Formulaciones de liberacion modificada para oprozomib
TR200900879A2 (tr) Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
MX2015013115A (es) Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue.
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
TR200900880A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik bileşimler.
TN2013000151A1 (en) Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections
TR201201022A2 (tr) Akciğer hastalıkları, karaciğer hastalıkları ve çeşitli enfeksiyonların semptomatik ve/veya terapötik tedavisinde kullanılan farmasötik bileşimler.
TR201714726A1 (tr) Antikolinerjik bir etken madde içeren farmasötik formülasyon.

Legal Events

Date Code Title Description
FG Grant of patent